Assessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer

IF 6 3区医学 Q1 CELL BIOLOGY

Cancer & Metabolism Pub Date : 2024-01-02 DOI:10.1186/s40170-023-00329-9

Federica Tambaro, Giovanni Imbimbo, Elisabetta Ferraro, Martina Andreini, Roberta Belli, Maria Ida Amabile, Cesarina Ramaccini, Giulia Lauteri, Giuseppe Nigri, Maurizio Muscaritoli, Alessio Molfino

{"title":"Assessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer","authors":"Federica Tambaro, Giovanni Imbimbo, Elisabetta Ferraro, Martina Andreini, Roberta Belli, Maria Ida Amabile, Cesarina Ramaccini, Giulia Lauteri, Giuseppe Nigri, Maurizio Muscaritoli, Alessio Molfino","doi":"10.1186/s40170-023-00329-9","DOIUrl":null,"url":null,"abstract":"Adipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy. For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia. We considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases. We collected SAT and total RNA was extracted and ATGL, HSL, PPARα, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5. We found higher expression of ATGL and HSL in GI cancer patients with respect to controls (p ≤ 0.008) and a trend of increase for PPARα (p = 0.055). We found an upregulation of ATGL in GI cancer patients with cachexia (p = 0.033) and without cachexia (p = 0.017) vs controls. HSL was higher in patients with cachexia (p = 0.020) and without cachexia (p = 0.021), compared to controls. ATGL was upregulated in gastric cancer vs controls (p = 0.014) and higher HSL was found in gastric (p = 0.008) and in pancreatic cancer (p = 0.033) vs controls. At the protein level, we found higher CGI-58 in cancer vs controls (p = 0.019) and in cachectic vs controls (p = 0.029), as well as in gastric cancer vs controls (p = 0.027). In our cohort of GI cancer patients, we found a modulation in the expression of genes and proteins involved in lipolysis, and differences were interestingly detected according to cancer type.","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":"103 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40170-023-00329-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Adipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy. For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia. We considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases. We collected SAT and total RNA was extracted and ATGL, HSL, PPARα, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5. We found higher expression of ATGL and HSL in GI cancer patients with respect to controls (p ≤ 0.008) and a trend of increase for PPARα (p = 0.055). We found an upregulation of ATGL in GI cancer patients with cachexia (p = 0.033) and without cachexia (p = 0.017) vs controls. HSL was higher in patients with cachexia (p = 0.020) and without cachexia (p = 0.021), compared to controls. ATGL was upregulated in gastric cancer vs controls (p = 0.014) and higher HSL was found in gastric (p = 0.008) and in pancreatic cancer (p = 0.033) vs controls. At the protein level, we found higher CGI-58 in cancer vs controls (p = 0.019) and in cachectic vs controls (p = 0.029), as well as in gastric cancer vs controls (p = 0.027). In our cohort of GI cancer patients, we found a modulation in the expression of genes and proteins involved in lipolysis, and differences were interestingly detected according to cancer type.

查看原文本刊更多论文

评估胃肠癌患者脂肪组织中的脂肪分解生物标志物

癌症患者的脂肪组织代谢可能会受损。特别是，在癌症促进脂肪组织萎缩的过程中，脂肪分解增加。为此，我们评估了胃肠道癌症患者皮下脂肪组织（SAT）中与脂肪分解相关的基因和蛋白质的表达情况，并与对照组进行了比较，以验证它们在癌症、不同类型的胃肠道癌症和恶病质中的参与情况。我们考虑了首次确诊时患有消化道癌症（胃癌、胰腺癌和结直肠癌）、伴有/不伴有恶病质的患者，以及患有良性疾病的对照组。我们收集了 SAT，提取了总 RNA，并通过 qRT-PCR 分析了 ATGL、HSL、PPARα 和 MCP1。对 CGI-58、PLIN1 和 PLIN5 进行了 Western 印迹分析。我们发现，与对照组相比，消化道癌症患者的 ATGL 和 HSL 表达量更高（p ≤ 0.008），PPARα 的表达量呈上升趋势（p = 0.055）。我们发现，与对照组相比，有恶病质（p = 0.033）和无恶病质（p = 0.017）的消化道癌症患者的 ATGL 上调。与对照组相比，恶病质患者（p = 0.020）和无恶病质患者（p = 0.021）的 HSL 均较高。胃癌与对照组相比，ATGL上调（p = 0.014），胃癌（p = 0.008）和胰腺癌（p = 0.033）与对照组相比，HSL较高。在蛋白质水平上，我们发现癌症患者与对照组相比（p = 0.019）、恶性肿瘤患者与对照组相比（p = 0.029）以及胃癌患者与对照组相比（p = 0.027），CGI-58 较高。在我们的消化道癌症患者队列中，我们发现参与脂肪分解的基因和蛋白质的表达发生了改变，而且有趣的是，根据癌症类型发现了差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer & Metabolism Multiple-

自引率

1.70%

发文量

审稿时长

14 weeks

期刊介绍： Cancer & Metabolism welcomes studies on all aspects of the relationship between cancer and metabolism, including: -Molecular biology and genetics of cancer metabolism -Whole-body metabolism, including diabetes and obesity, in relation to cancer -Metabolomics in relation to cancer; -Metabolism-based imaging -Preclinical and clinical studies of metabolism-related cancer therapies.